Clinical Trial

Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG

Study acronym: CMD03DIPG
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 30, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-15; most recent amendment 2025-03-27.
Status change: Not Yet Recruiting → Recruiting 2024-04-18
Trial Details
NCT Number NCT06221553
Lead Sponsor Chulalongkorn University
Collaborators: King Chulalongkorn Memorial Hospital
Conditions DIPG Brain Tumor, Diffuse Intrinsic Pontine Glioma
Enrollment 9 participants
Start Date 2024-03-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-30